个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

A Randomized, Double-Blind, Positive-Controlled, Multicenter Clinical Trial on the Efficacy and Safety of ShuganJieyu Capsule and St. John's Wort for Major Depressive Disorder with Somatic Complaints

| 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ SSCI

作者：
Xiang, Yajie[1,2,3] * ; Wang, Lihua[4] * ; Gu, Ping[5] * ; Wang, Chunxue[6] * ; Tian, Yuling[7] * ; Shi, Wanying[8] * ; Deng, Fang[9] * ; Zhang, Yongbo[10] * ; Gao, Li[11] * ; Wang, Kai[12] ; Wang, Yi[13] ; He, Jincai[14] ; Zhao, Wenfeng[15] ; Bi, Xiaoying[16] ; Hu, Jian[17] ; Zhong, Lianmei[18] ; Guo, Yi[19] ; Zhou, Xinyu[2,3,20] ; Wang, Hongxing[14] ; Xie, Peng[1,2,3] ;
机构： [1]Chongqing Med Univ, Affiliated Hosp 1, Dept Neurol, Chongqing, Peoples R China [2]Chongqing Med Univ, Affiliated Hosp 1, NHC Key Lab Diag & Treatment Brain Funct Dis, Chongqing, Peoples R China [3]Chongqing Key Lab Neurobiol, Chongqing, Peoples R China [4]Harbin Med Univ, Affiliated Hosp 2, Dept Neurol, Harbin, Heilongjiang, Peoples R China [5]First Hosp Hebei Med Univ, Dept Neurol, Shijiazhuang, Hebei, Peoples R China [6]Capital Med Univ, Beijing Tiantan Hosp, Dept Neuropsychiat & Behav Neurol, Beijing, Peoples R China [7]First Hosp Shanxi Med Univ, Dept Neurol, Taiyuan, Shanxi, Peoples R China [8]Shijiazhuang First Hosp, Dept Neurol, Shijiazhuang, Hebei, Peoples R China [9]First Hosp Jilin Univ, Dept Neurol, Changchun, Jilin, Peoples R China [10]Capital Med Univ, Beijing Friendship Hosp, Dept Neurol, Beijing, Peoples R China [11]Third Peoples Hosp Chengdu, Dept Neurol, Chengdu, Sichuan, Peoples R China [12]Anhui Med Univ, Affiliated Hosp 1, Dept Med Psychol, Hefei, Anhui, Peoples R China [13]Fudan Univ, Huashan Hosp, Dept Neurol, Shanghai, Peoples R China [14]Wenzhou Med Univ, Affiliated Hosp 1, Dept Anaesthesiol, Wenzhou, Zhejiang, Peoples R China [15]Capital Med Univ, Xuanwu Hosp, Natl Ctr Neurol Disorders, Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China [16]Second Mil Med Univ, Changhai Hosp, Dept Neurol, Shanghai, Peoples R China [17]Harbin Med Univ, Affiliated Hosp 1, Dept Psychiat, Harbin, Heilongjiang, Peoples R China [18]Kunming Med Univ, Affiliated Hosp 1, Dept Neurol, Kunming, Yunnan, Peoples R China [19]Jinan Univ, Clin Med Coll 2, Dept Neurol, Shenzhen, Guangdong, Peoples R China [20]Chongqing Med Univ, Affiliated Hosp 1, Dept Psychiat, Chongqing, Peoples R China
出处：
DOI： 10.1007/s11469-023-01222-8
ISSN：

关键词： Major depressive disorder Somatic complaints Randomized controlled trial ShuganJieyu capsule St John's wort

摘要：
Previous studies have found the effect of ShuganJieyu capsule and St. John's wort on the treatment of depression and explored their potential benefits for somatic symptoms, while the evidence of comparison of them for depression with somatic complaints is lacking. In this multicenter randomized controlled trial, 198 major depressive disorder (MDD) patients with somatic complaints were randomly allocated, 92 in the ShuganJieyu capsule group, and 91 in the St. John's wort group completed 8 weeks treatment. Primary outcome was the change score of the 17-item Hamilton Depression Rating Scale (HDRS-17) at week 8. Secondary outcomes included other indices of depression, somatic symptoms, anxiety, insomnia, quality of life, and adverse events. The change scores of HDRS-17 were not significantly difference between the two groups, but the reduction in HDRS-17 was significantly improved in both the ShuganJieyu capsule (HDRS-17 Delta = - 11.35 +/- 5.38, p < 0.001) and St. John's wort (HDRS-17 Delta = - 11.20 +/- 5.71, p < 0.001) groups. The other outcomes showed similar results. Compared with St. John's wort, the ShuganJieyu capsule induced significantly greater HDRS-17 reductions in male (SMD, - 0.55; 95% CI, - 1.08 to - 0.02) but not in female. Overall, The ShuganJieyu capsule was comparable to St. John's wort as a complementary and alternative intervention for MDD patients with somatic complaints in the acute treatment, especially for male patients.

基金：
National Key R&D Program of China; Society of Neuropsychological and Affective Disorders, Chinese Neurology Association
语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类 | 3 区 医学
小类 | 4 区 精神病学 4 区 心理学：临床 4 区 药物滥用
JCR分区：
出版当年[2023]版：
Q1 SUBSTANCE ABUSE Q1 PSYCHOLOGY, CLINICAL Q2 PSYCHIATRY
最新[2023]版：
Q1 SUBSTANCE ABUSE Q1 PSYCHOLOGY, CLINICAL Q2 PSYCHIATRY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Chongqing Med Univ, Affiliated Hosp 1, Dept Neurol, Chongqing, Peoples R China [2]Chongqing Med Univ, Affiliated Hosp 1, NHC Key Lab Diag & Treatment Brain Funct Dis, Chongqing, Peoples R China [3]Chongqing Key Lab Neurobiol, Chongqing, Peoples R China
共同第一作者：
通讯作者：
通讯机构： [1]Chongqing Med Univ, Affiliated Hosp 1, Dept Neurol, Chongqing, Peoples R China [2]Chongqing Med Univ, Affiliated Hosp 1, NHC Key Lab Diag & Treatment Brain Funct Dis, Chongqing, Peoples R China [3]Chongqing Key Lab Neurobiol, Chongqing, Peoples R China
推荐引用方式(GB/T 7714)：
Xiang Yajie,Wang Lihua,Gu Ping,et al.A Randomized, Double-Blind, Positive-Controlled, Multicenter Clinical Trial on the Efficacy and Safety of ShuganJieyu Capsule and St. John's Wort for Major Depressive Disorder with Somatic Complaints[J].INTERNATIONAL JOURNAL OF MENTAL HEALTH AND ADDICTION.2023,doi:10.1007/s11469-023-01222-8.
APA：
Xiang, Yajie,Wang, Lihua,Gu, Ping,Wang, Chunxue,Tian, Yuling...&Xie, Peng.(2023).A Randomized, Double-Blind, Positive-Controlled, Multicenter Clinical Trial on the Efficacy and Safety of ShuganJieyu Capsule and St. John's Wort for Major Depressive Disorder with Somatic Complaints.INTERNATIONAL JOURNAL OF MENTAL HEALTH AND ADDICTION,,
MLA：
Xiang, Yajie,et al."A Randomized, Double-Blind, Positive-Controlled, Multicenter Clinical Trial on the Efficacy and Safety of ShuganJieyu Capsule and St. John's Wort for Major Depressive Disorder with Somatic Complaints".INTERNATIONAL JOURNAL OF MENTAL HEALTH AND ADDICTION .(2023)

相关文献

[1]Correction: A Randomized, Double-Blind, Positive-Controlled, Multicenter Clinical Trial on the Efficacy and Safety of ShuganJieyu Capsule and St. John's Wort for Major Depressive Disorder with Somatic Complaints [2]Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial. [3]舒肝解郁胶囊治疗轻中度抑郁症的随机双盲安慰剂对照研究 [4]Duloxetine Enteric-coated Tablets Versus Paroxetine in the Treatment of Major Depressive Disorder: A Double-blind, Double-dummy, Randomized Controlled Clinical Trial [5]A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major depressive disorder [6]Once-daily duloxetine 60 mg in the treatment of major depressive disorder: Multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil [7]A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder [8]Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial. [9]Treatment of major depressive disorders with generic duloxetine and paroxetine: a multi-centered, double-blind, double-dummy, randomized controlled clinical trial [10]Transcriptomic decoding of regional cortical vulnerability to major depressive disorder

资源点击量：57189 今日访问量：0 总访问量：1788 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持：重庆聚合科技有限公司 地址：云南省昆明市西昌路295号(650032)